| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Clearside Biomedical, Inc.
13D/A
CLSD · 185063104
|
0.4% |
2/21/2025
Event 9/13/2024
|
||||
| Hatteras Venture Advisors IV SBIC, LLC | 0% | |||||
| Hatteras Venture Partners IV SBIC, LP | 0% | |||||
| Hatteras Venture Advisors IV, LLC | 0% | |||||
| Hatteras Venture Partners IV, LP | 0% | |||||
| Hatteras NC Fund, LP | 0% | |||||
| John C. Crumpler | 0.2% | |||||
| Robert A. Ingram | 0.2% | |||||
| Kenneth B. Lee | 0.1% | |||||
| Clay B. Thorp | 0.4% | |||||
| Douglas Reed | 0.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.